Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective

Saved in:

Bibliographic Details
Published in:	JAMA internal medicine Vol. 181; no. 10; p. 1276
Main Authors:	Dunn, Billy, Stein, Peter, Cavazzoni, Patrizia
Format:	Journal Article
Language:	English
Published:	United States 01.10.2021
Subjects:	Alzheimer Disease - diagnosis Alzheimer Disease - drug therapy Amyloid beta-Peptides - antagonists & inhibitors Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - economics Brain - diagnostic imaging Brain - pathology Decision Making Dose-Response Relationship, Drug Drug Approval - methods Humans Infusions, Intravenous - methods Magnetic Resonance Imaging - methods Nootropic Agents - administration & dosage Nootropic Agents - adverse effects Nootropic Agents - economics Plaque, Amyloid - diagnostic imaging Positron-Emission Tomography - methods Product Surveillance, Postmarketing Randomized Controlled Trials as Topic - methods Treatment Outcome United States United States
ISSN:	2168-6114, 2168-6114
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!